Chemotherapy Plus Gefitinib Followed by Chemotherapy, Radiation Therapy, and Gefitinib For Head and Neck Cancer
Although gefitinib has been combined successfully with various chemotherapeutic regimens with minimal increase in overall toxicity, experience with concurrent radiation therapy is limited. In this trial, we will evaluate the feasibility, toxicity, and effectiveness a novel combination of chemotherapy, radiation therapy, and gefitinib.
Head and Neck Cancer
DRUG: Gefitinib|DRUG: Docetaxel|DRUG: Carboplatin|DRUG: Fluorouracil
Overall response rate
Overall survival|Time to progression|Overall toxicity
Upon determination of eligibility, patients will receive:

Induction Therapy

* Docetaxel
* Carboplatin
* 5-FU
* Gefitinib

Combined Modality Therapy

Cohort 1:

* Radiation therapy
* Gefitinib

Cohort 2:

* Radiation therapy
* Gefitinib
* Docetaxel